Abeona Therapeutics Announces Third-Quarter 2026 Financial Results
Abeona Therapeutics has released its financial figures covering the third quarter of 2026, highlighting performance relative to market expectations.
Earnings and Revenue Performance
During the third quarter of 2026, Abeona Therapeutics reported a GAAP earnings per share (EPS) of -$0.08, surpassing consensus projections by $0.10. However, the company's revenue for the quarter reached $13.49 million, falling short of expectations by $1.33 million.
Balance Sheet and Cash Position
The company's financial report also detailed its liquidity reserves. As of September 30, 2026, Abeona Therapeutics held $134.9 million in cash, cash equivalents, and short-term investments. This represents a change from the previous quarter's end on June 30, 2026, when cash, cash equivalents, and short-term investments stood at $146.8 million.
Market Reaction
Following the release of the third-quarter financial results, trading activity in pre-market sessions indicated downward movement, with shares declining by 2.6%.
Additional updates and presentations from the company during the period included commentary on commercial developments such as Zevaskyn, as well as presentations at industry events including the Morgan Stanley 24th Annual Global Healthcare Conference.
